E-DRUG: Neglected disease drug development
------------------------------------------
E-drug has learned [Thanks Philippa, for the tip!] that an interesting, well-documented report "THE NEW LANDSCAPE OF NEGLECTED DISEASE DRUG DEVELOPMENT" was published September 2005 by the Wellcome Trust. It was written by the Pharmaceutical R&D Policy Project at the LSE Health and Social Care Unit.
An executive summary is available at www.wellcome.ac.uk/assets/wtx026593.pdf
The full 102 page report is downloadable at http://www.wellcome.ac.uk/assets/wtx026592.pdf
An extract from the Table of content:
SECTION 01
THE NEW LANDSCAPE OF NEGLECTED DISEASE
DRUG RESEARCH & DEVELOPMENT 6
1.1 BACKGROUND 6
1.2 MULTINATIONAL PHARMACEUTICAL COMPANIES 10
1.3 SMALL COMPANY ACTIVITY 18
1.4 DEVELOPING COUNTRY FIRMS 28
1.5 PUBLIC-PRIVATE PARTNERSHIPS 30
SECTION 02
PERFORMANCE METRICS 40
2.1 INTRODUCTION 40
2.2 HEALTH VALUE FOR DEVELOPING COUNTRY PATIENTS 40
2.3 LEVEL OF INNOVATION 50
2.4 CAPACITY (ability to make drugs) 52
2.5 DEVELOPMENT TIMES 55
2.6 COST AND COST-EFFICIENCY 58
2.7 CORRELATES OF SUCCESS 61
SECTION 03
RECOMMENDATIONS 63
3.1 OPTIMAL APPROACHES 63
3.2 POLICIES TO SUPPORT PPPs 68
3.3 POLICIES TO INCREASE SMALL COMPANY COMMERCIAL
NEGLECTED DISEASE ACTIVITY 74
3.4 A NEW FUNDRAISING MECHANISM: THE NEGLECTED DISEASE
FAST TRACK OPTION 76
3.5 OTHER APPROACHES 80
3.6 CREATING A PUBLIC ‘MARKET’? 81
ANNEXES 83
REFERENCES 93
For more information, contact:
Pharmaceutical R&D Policy Project
LSE Health and Social Care
Houghton Street
London WC2A 2AE
Tel: +44 (0)20 7852 3615
+44 (0)20 7852 3690
Email: j.guzman@lse.ac.uk
m.moran@lse.ac.uk
j.r.diaz@lse.ac.uk
For further copies please contact:
Publications Department, The Wellcome Trust
Tel: +44 (0)20 7611 8651
Email: publishing@wellcome.ac.uk
Any E-drugger who wants to review the publication or discuss its recommendations?
---------
Wilbert Bannenberg, E-drug moderator
Email: wjb@planet.nl
The 1995-2004 E-drug archives are at http://www.essentialdrugs.org/edrug/
(un)Subscribe E-drug at:
http://list.healthnet.org/mailman/listinfo/e-drug